المؤلفون: Rozeman, EA, Menzies, AM, van Akkooi, ACJ, Adhikari, C, Bierman, C, van de Wiel, BA, Scolyer, RA, Krijgsman, O, Sikorska, K, Eriksson, H, Broeks, A, van Thienen, JV, Guminski, AD, Acosta, AT, ter Meulen, S, Koenen, AM, Bosch, LJW, Shannon, K, Pronk, LM, Gonzalez, M, Ch'ng, S, Grijpink-Ongering, LG, Stretch, J, Heijmink, S, van Tinteren, H, Haanen, JBAG, Nieweg, OE, Klop, WMC, Zuur, CL, Saw, RPM, van Houdt, WJ, Peeper, DS, Spillane, AJ, Hansson, J, Schumacher, TN, Long, GV, Blank, CU

المصدر: The Lancet. Oncology. 20(7):948-960

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:141312149

المؤلفون: Pronk, LM, Piena, M, Van de Pas, M, Jakouloff, D, Giesen, E

المصدر: In Value in Health December 2022 25(12) Supplement:S308-S308

المؤلفون: Rozeman, EA, Van Akkooi, ACJ, Menzies, AM, Smith, M, Scolyer, RA, Pronk, LM, Gonzales, M, Hoeller, C, Hansson, J, Larkin, JMG, Long, GV, Blank, CU

المصدر: JOURNAL OF CLINICAL ONCOLOGY. 36(15)

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:139071135

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Rohaan MW; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gomez-Eerland R; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Berg JH; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Geukes Foppen MH; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Zon M; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Raud B; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Jedema I; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Scheij S; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Boer R; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bakker NAM; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., Pronk LM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sari A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kessels R; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Haak M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Mallo HA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Karger M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Wiel BA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Zuur CL; Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands., Duinkerken CW; Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands., Lalezari F; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Thienen JV; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Wilgenhof S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Nuijen B; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schumacher TN; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

المصدر: Immuno-oncology technology [Immunooncol Technol] 2022 Jun 18; Vol. 15, pp. 100089. Date of Electronic Publication: 2022 Jun 18 (Print Publication: 2022).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 9918281581106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0188 (Electronic) Linking ISSN: 25900188 NLM ISO Abbreviation: Immunooncol Technol Subsets: PubMed not MEDLINE

المؤلفون: Verhaart SL; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, United Kingdom., Abu-Ghanem Y; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Mulder SF; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Oosting S; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands., Van Der Veldt A; Department of Medical Oncology, Erasmus Medical Center-Cancer Institute, Rotterdam, The Netherlands., Osanto S; Department of Medical Oncology, Leids University Medical Center, Leiden, The Netherlands., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., Houtsma D; Department of Medical Oncology, HAGA Hospital, The Hague, The Netherlands., Peters FPJ; Department of Medical Oncology, Zuyderland Hospital, Sittard - Geleen, The Netherlands., Groenewegen G; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Pronk LM; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Tascilar M; Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands., Hamberg P; Department of Medical Oncology, Franciscus Gasthuis and Vllietland, Rotterdam, The Netherlands., Los M; Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, The Netherlands., Vreugdenhil G; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Polee M; Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Ten Tije AJ; Department of Medical Oncology, Amphia Hospital, Breda, The Netherlands., Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bex A; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands; Division of Surgery and Interventional Science, University College London, London, United Kingdom; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: axel.bex@nhs.net., van den Eertwegh AJ; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, United Kingdom.

المصدر: Clinical genitourinary cancer [Clin Genitourin Cancer] 2021 Jun; Vol. 19 (3), pp. 274.e1-274.e16. Date of Electronic Publication: 2020 Oct 14.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell*/drug therapy , Kidney Neoplasms*/drug therapy, Biomarkers ; Humans ; Netherlands ; Nivolumab/adverse effects ; Retrospective Studies

المؤلفون: van den Berg JH; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Heemskerk B; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Rooij N; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gomez-Eerland R; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Michels S; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Zon M; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Boer R; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bakker NAM; BioTherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Jorritsma-Smit A; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Buuren MM; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kvistborg P; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Spits H; AIMM Therapeutics, Amsterdam, The Netherlands.; Experimental Immunology, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, The Netherlands., Schotte R; AIMM Therapeutics, Amsterdam, The Netherlands., Mallo H; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Karger M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Hage JA; Department of Surgery, Leiden Universitair Medisch Centrum, Leiden, Zuid-Holland, The Netherlands., Wouters MWJM; Surgical Oncology, Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, The Netherlands.; Dutch Institute for Clinical Auditing, Leiden, The Netherlands., Pronk LM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Geukes Foppen MH; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University Department of Pharmaceutical Sciences, Utrecht, Utrecht, The Netherlands., Nuijen B; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schumacher TN; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Haanen JBAG; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands j.haanen@nki.nl.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Aug; Vol. 8 (2).

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Lymphocytes, Tumor-Infiltrating/*metabolism , Melanoma/*genetics , T-Lymphocytes/*metabolism, Adult ; Aged ; Female ; Follow-Up Studies ; Humans ; Male ; Melanoma/pathology ; Middle Aged

المؤلفون: Blank CU; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl., Rozeman EA; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Fanchi LF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sikorska K; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Wiel B; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kvistborg P; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Krijgsman O; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Braber M; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Philips D; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Broeks A; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Thienen JV; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Mallo HA; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Adriaansz S; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Ter Meulen S; Surgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Pronk LM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bruining A; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gittelman RM; Adaptive Biotechnologies, Seattle, WA, USA., Warren S; NanoString Technologies, Inc., Seattle, WA, USA., van Tinteren H; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Peeper DS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JBAG; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Akkooi ACJ; Surgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schumacher TN; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. t.schumacher@nki.nl.

المصدر: Nature medicine [Nat Med] 2018 Nov; Vol. 24 (11), pp. 1655-1661. Date of Electronic Publication: 2018 Oct 08.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

مواضيع طبية MeSH: Chemotherapy, Adjuvant/*methods , Ipilimumab/*administration & dosage , Melanoma/*drug therapy , Nivolumab/*administration & dosage, Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; Chemotherapy, Adjuvant/adverse effects ; Disease-Free Survival ; Humans ; Ipilimumab/adverse effects ; Male ; Melanoma/pathology ; Melanoma/surgery ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Neoplasm Staging ; Nivolumab/adverse effects

المؤلفون: Biró E; Department of Clinical Chemistry, F-1-219, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD, Amsterdam, Netherlands. E.Biro@amc.nl, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A, Hack CE

المصدر: Annals of the rheumatic diseases [Ann Rheum Dis] 2007 Aug; Vol. 66 (8), pp. 1085-92. Date of Electronic Publication: 2007 Jan 29.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0003-4967 (Print) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE

مواضيع طبية MeSH: Complement Activation* , Complement Pathway, Classical*, Arthritis, Rheumatoid/*immunology , Synovial Fluid/*chemistry, Aged ; Analysis of Variance ; Arthritis, Rheumatoid/blood ; C-Reactive Protein/analysis ; Case-Control Studies ; Complement C1q/analysis ; Complement C3/analysis ; Complement C4/analysis ; Female ; Humans ; Immunoglobulin G/analysis ; Immunoglobulin G/blood ; Immunoglobulin M/analysis ; Immunoglobulin M/blood ; Knee Joint ; Male ; Middle Aged ; Synovial Fluid/immunology